251 related articles for article (PubMed ID: 37235767)
41. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
42. Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders.
Corbella-Bagot L; Riquelme-McLoughlin C; Morgado-Carrasco D
Actas Dermosifiliogr; 2023 Oct; 114(9):T784-T801. PubMed ID: 37543140
[TBL] [Abstract][Full Text] [Related]
43. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
[TBL] [Abstract][Full Text] [Related]
44. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
45. Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Gómez-García F; Gómez-Arias PJ; Hernandez J; Montilla AM; Gay-Mimbrera J; Aguilar-Luque M; Viguera-Guerra I; Velez García-Nieto A; Isla-Tejera B; Ruano J
BMJ Open; 2019 May; 9(5):e028303. PubMed ID: 31122999
[TBL] [Abstract][Full Text] [Related]
46. JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
Aihie O; Dyer JA
Mo Med; 2023; 120(1):45-48. PubMed ID: 36860609
[TBL] [Abstract][Full Text] [Related]
47. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature.
Li H; Wang H; Qiao G; Liu Y; Zhang F; Pan F
Int Immunopharmacol; 2023 Sep; 122():110591. PubMed ID: 37441809
[TBL] [Abstract][Full Text] [Related]
48. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
49. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
Chapman S; Kwa M; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
[TBL] [Abstract][Full Text] [Related]
50. New small molecules in dermatology: for the autoimmunity, inflammation and beyond.
Criado PR; Lorenzini D; Miot HA; Bueno-Filho R; Carneiro FRO; Ianhez M
Inflamm Res; 2023 Jun; 72(6):1257-1274. PubMed ID: 37212867
[TBL] [Abstract][Full Text] [Related]
51. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
De SK
Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
[TBL] [Abstract][Full Text] [Related]
52. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
53. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Zhang L; Du D; Wang L; Guo L; Jiang X
J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
[TBL] [Abstract][Full Text] [Related]
55. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
56. Emerging therapies for atopic dermatitis: JAK inhibitors.
Cotter DG; Schairer D; Eichenfield L
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
[TBL] [Abstract][Full Text] [Related]
57. Application of Baricitinib in Dermatology.
Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F
J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989
[TBL] [Abstract][Full Text] [Related]
58. JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis.
Wu J; Li L; Zhu Q; Zhang T; Miao F; Cui Z; Dong G; Tai Z; Chen Z
Biomed Pharmacother; 2024 Feb; 171():116167. PubMed ID: 38262152
[TBL] [Abstract][Full Text] [Related]
59. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
60. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.
Smith P; Yao W; Shepard S; Covington M; Lee J; Lofland J; Naim A; Sheth T; Parikh B; Yeleswaram S
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
